Filing Flows › Alector (ALEC) › Guidance & outlook
Alector (ALEC) guidance and outlook
Alector's 10-Q filed Nov 5, 2026 makes 22 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-Q filed Nov 5, 2026
- Our pipeline is built around the Alector Brain Carrier (ABC) platform, a proprietary blood-brain barrier (BBB) technology that enables diverse therapeutic modalities, including antibodies, enzymes, proteins and siRNA, to reach genetically validated targets in the central nervous system.
- These proprietary features are intended to balance brain uptake, potency, and safety across our pipeline.
- Our next-generation portfolio, built on the ABC platform and distinct from our prior clinical programs, is designed to address neurodegenerative diseases through targeted mechanisms, including the removal of pathogenic proteins, replacement of deficient proteins, and restoration of normal cellular function.
- We submitted a registration to a Human Research Ethics Committee (HREC) in Australia in October 2026 and are targeting first-in-human SC dosing in Australia by April 2027.
- We are also targeting submission of a U.S.
- We are targeting first-in-human studies in the second quarter of 2028.
- Further, we do not expect to generate revenue from product sales until such time, if ever, that we are able to successfully complete the development and obtain marketing approval for one of our product candidates.
- We will continue to require additional capital to develop our product candidates, advance our research and preclinical programs, and fund operations for the foreseeable future.
- We have incurred net losses in each year since inception, and we expect to continue to incur net losses for the foreseeable future.
- We expect our expenses will increase substantially in connection with our ongoing activities, as we:
- On October 21, 2025, we committed to a plan to reduce our workforce by approximately 47% in order to align resources with the Company’s strategic priorities following the results of the Phase 3 INFRONT-3 clinical trial evaluating the safety and efficacy of latozinemab (AL001) in individuals with frontotemporal dementia due to a GRN mutation (FTD- GRN ).
- Together with the $100.0 million upfront payment we received subsequent to September 30, 2026, under the Genentech License Agreement, net of the $15.0 million payment made to Spur under the Spur Agreement on November 2, 2026, and the net proceeds from the October 2026 underwritten offering, we anticipate that our existing cash, cash equivalents, and marketable securities will enable us to fund our operations into…
Alector's latest quarter
Alector, Q3 2026: revenue $163M (50× year over year), operating margin 76.0%, net earnings $125M, operating cash flow −$24.2M. The chart follows the revenue to costs, profit and cash.
Questions
What does Alector expect?
Our pipeline is built around the Alector Brain Carrier (ABC) platform, a proprietary blood-brain barrier (BBB) technology that enables diverse therapeutic modalities, including antibodies, enzymes, proteins and siRNA, to reach genetically validated targets in the central nervous system. These proprietary features are intended to balance brain uptake, potency, and safety across our pipeline. Our next-generation portfolio, built on the ABC platform and distinct from our prior clinical programs, is designed to address neurodegenerative diseases through targeted mechanisms, including the removal o
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.